Focus on the clinical frontiers of cancer! The 2019 China Cancer Congress was held.

(Health Times reporter Xu Wei) malignant tumor has become the number one threat to the health of our people, is currently China's largest public health problem. June 27-30, sponsored by the Chinese Medical Association, the Chinese Medical Association Oncology Credit Association, the Guangdong Medical Association Oncology Credit Association, Zhongshan University Cancer Prevention and Control Center, the 2019 China Cancer Congress co-sponsored by the China Southern Cancer Research Association held in Guangzhou.
the opening ceremony of the 2019 Chinese Cancer Congress
the conference was held with the theme of "information exchange accurate, famous doctors converge to solve problems" as the theme, the Chinese Medical Association Oncology Credit Union 11th Chairman, the Chinese Medical University affiliated With the First Hospital Oncology Center Director Xu Huimian, Zhongshan University affiliated Oncology Hospital President Xu Ruihua, the Chinese Medical Association Of the Cancer Association Of the President-designate, Sun Yat-sen University affiliated Oncology Hospital Professor Lin Yu as the President of the General Assembly. Cao Zeyi, former vice-minister of the Ministry of Health, Yao Zhibin, vice chairman of the Guangdong Provincial Committee of the Chinese People's Political Consultative Conference, Yu Minbin, deputy secretary of the Party Committee of Zhongshan University, Xu Huimian, chairman of the 11th Committee of the Oncology Society of the Chinese Medical Association, and Xu Ruihua, president of sun yat-sen University Affiliated Oncology Hospital, addressed the conference.
has made progress and breakthroughs in the field of cancer prevention and treatment in China after several generations of cancer prevention and treatment. However, in the concrete practice, in the face of complex information, how to cooperate through multidisciplinary cooperation, according to the individual differences of patients accurate diagnosis and treatment needs to be further standardized.Xu Huimian, chairman of the 11th Committee of the Chinese Medical Association's Oncology Credit Society and director of the First Hospital Oncology Center affiliated with the Chinese Medical University, said in his speech that the Chinese Medical Association Oncology Association has a great responsibility and a difficult task.
In June 2018, the 11th Annual Meeting of the Oncology Credit Society of the Chinese Medical Association will be renamed the China Cancer Congress to highlight the influence of the Cancer Credit Society and its academic leadership. The conference is also one of the three major medical conferences recommended by the Chinese Association of Science and Technology in 2019.
Conference invited academicians from the oncology community such as Yu Jia, Yu Xishan, Yu Jinming and Lin Dongxuan to participate in and deliver keynote speeches.
from the point of view of improving cancer survival rate, a number of academicians advocate early diagnosis and treatment. Taking liver cancer as an example, Academician Yu Jia pointed out that liver cancer is still one of the biggest challenges, With 55% of the world's new liver cancer, China's liver cancer rate is the fourth, the death rate is third, the five-year survival rate is only 14%, and the recurrence rate after surgery is as high as 60%-70%. In order to improve the overall survival rate of cancer, early diagnosis and early treatment and anti-metastasis are the key.
's academician stoic on breast cancer as the theme speech pointed out that breast cancer has become a curable disease, breast cancer patients in Europe and the United States have a 5-year survival rate of up to 90%, compared with China has not yet established a breast cancer prevention and control system, 5-year survival rate of only 73%, significantly lower than in Europe and the United States.
, Dr. Lin Dongxuan pointed out that improving the long-term survival rate of stomach cancer is the purpose of future research. From the current treatment situation, esophageal cancer five-year survival rate of only about 30% or less. Most esophageal cancer patients are already in the middle and late stage of diagnosis, so survival is expected to be poor.
from the perspective of cancer treatment, Yu Jinming academician shared the new practice of radiation immunotherapy. Yu Jinming pointed out that the future radiotherapy will have early diagnosis technology of tumor, improve the proportion of radiotherapy treatment, radiotherapy and immunotherapy, and artificial intelligence and big data in the clinical application of radiotherapy and so on.
conference also invited the industry's top experts to participate in multi-tumor, multidisciplinary cross-topic academic forum. Including liver tumors, colorectal tumors, lymphomas, breast tumors, gastrointestinal tumors, oncology, gynecological tumors, lung tumors, pancreatic tumors, thyroid tumors, tumor conversion medicine, the Youth Committee, and the Chinese Medical Association Oncology Oncology Early Diagnosis and Early Treatment Group experts review 13 branch academic meetings, focusing on the clinical frontiers of tumors, promoting multidisciplinary, individual comprehensive treatment model.
in addition, the conference in particular increased the "Chinese Oncology Tomorrow", with a view to promoting the training of young oncologists.
.